Bio-Day, a technology seminar focused on Life Science
3 July 2012 | By HORIBA Scientific
HORIBA Scientific, organizes its first Technology Seminar focused on Life Sciences...
List view / Grid view
News
European Commission positive decision on flutiform®
3 July 2012 | By FTI Consulting
The European Commission has adopted a legally binding decision in favour of granting of marketing authorisations for flutiform®...
GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and numerous states
2 July 2012 | By GlaxoSmithKline
Agreement reached with the US Government...
Lonza expands its XS Microbial Expression Technology™ Toolbox by adding new alternative host organisms
Lonza, a world leader in biopharmaceutical development technologies, announced today the addition of two new host organisms and their associated systems to its XS Technology™ Platform. The expanded XS Technology™ Toolbox addresses the diversity of microbially-derived proteins by providing complementary expression systems that quickly deliver simple, reliable, high yielding cGMP…
NovoPen® 5 wins the red dot Best of the Best design award
2 July 2012 | By Novo Nordisk
Novo Nordisk awarded the red dot Best of the Best prize for its next-generation insulin injection pen, the NovoPen® 5...
GSK and Theravance announce positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD
2 July 2012 | By GlaxoSmithKline
Results from the pivotal efficacy studies...
Introducing TSI’s BioTrak™ Real-Time Viable Particle Counter
2 July 2012 | By TSI
The latest innovation in rapid microbiology method instrument technology is real-time viable detectors...
Bristol-Myers Squibb and AstraZeneca expand diabetes alliance through Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals
30 June 2012 | By AstraZeneca
Bristol-Myers Squibb to acquire Amylin...
Avacta expands following Aptuscan acquisition
29 June 2012 | By kdm communications limited
Avacta Group has expanded its Yorkshire headquarters with the addition of new laboratory, office and manufacturing space...
Biogen Idec and Isis announce global collaboration for antisense program targeting myotonic dystrophy
29 June 2012 | By Biogen Idec
Isis expands its rare disease franchise to include DM1...
GSK sets 20 July for expiration of tender offer to acquire Human Genome Sciences
29 June 2012 | By GlaxoSmithKline
Expiration is after HGS process bid deadline of 16 July...
Marketing and manufacturing approval received for TENELIA(R) 20mg tablets
29 June 2012 | By Daiichi Sankyo
A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan...
Syrris celebrates successful flow and automated process chemistry seminars
28 June 2012 | By kdm communications limited
Syrris’ latest free flow chemistry and automated process chemistry seminars, held during May in Dinslaken, Germany...
Gilead submits New Drug Application to U.S. FDA for boosting agent cobicistat
28 June 2012 | By Gilead Sciences
Gilead Sciences has submitted a New Drug Application to the U.S. FDA for marketing approval of cobicistat...
Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride
28 June 2012 | By Boehringer Ingelheim
Results from a two-year study published in The Lancet today demonstrate that Trajenta® (linagliptin) provides similar blood glucose improvements when compared to the commonly prescribed sulphonylurea, glimepiride, in adult patients with type 2 diabetes (T2D) inadequately controlled on metformin alone. The publication also describes that linagliptin was associated with significantly…
